These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30088965)

  • 1. Will Courts Allow States to Regulate Drug Prices?
    Robertson C
    N Engl J Med; 2018 Sep; 379(11):1000-1002. PubMed ID: 30088965
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.
    Greene JA; Padula WV
    N Engl J Med; 2017 Jul; 377(2):101-103. PubMed ID: 28591520
    [No Abstract]   [Full Text] [Related]  

  • 3. Limiting State Flexibility in Drug Pricing.
    Bagley N; Sachs RE
    N Engl J Med; 2018 Sep; 379(11):1002-1004. PubMed ID: 30207910
    [No Abstract]   [Full Text] [Related]  

  • 4. Legal Challenges to State Drug Pricing Laws.
    Lee TT; Kesselheim AS; Kapczynski A
    JAMA; 2018 Mar; 319(9):865-866. PubMed ID: 29435585
    [No Abstract]   [Full Text] [Related]  

  • 5. Possible anticompetitive agreements between brand, generic companies to be studied.
    Landis NT
    Am J Health Syst Pharm; 2000 Dec; 57(23):2140, 2142. PubMed ID: 11127691
    [No Abstract]   [Full Text] [Related]  

  • 6. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 7. States on the Front Line: Addressing America's Drug Pricing Problem.
    Riley T; Lanford S
    J Leg Med; 2019; 39(2):81-93. PubMed ID: 31503529
    [No Abstract]   [Full Text] [Related]  

  • 8. The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules.
    Scott Morton F
    Rand J Econ; 1997; 28(2):269-90. PubMed ID: 11794358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceuticals and medical devices: cost savings.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
    [No Abstract]   [Full Text] [Related]  

  • 10. States as Activists.
    Buck ID
    J Leg Med; 2019; 39(2):121-136. PubMed ID: 31503528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
    Sinha MS; Curfman GD; Carrier MA
    JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
    [No Abstract]   [Full Text] [Related]  

  • 12. A few specialty drug prices fall--all generics.
    Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766
    [No Abstract]   [Full Text] [Related]  

  • 13. Price controls and global pharmaceutical progress.
    Scherer FM
    Health Aff (Millwood); 2009; 28(1):w161-4. PubMed ID: 19088103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 15. Addressing Pharmaceutical Price Spikes Through Generic Preclearance.
    Sachs RE
    J Leg Med; 2019; 39(2):169-176. PubMed ID: 31503530
    [No Abstract]   [Full Text] [Related]  

  • 16. Prescription drug prices in the US.
    Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 18. Key compliance concerns for the generic pharmaceutical industry.
    Werling K; Enyeart A
    Health Care Law Mon; 2009 Jul; 2009(7):2-6. PubMed ID: 19618761
    [No Abstract]   [Full Text] [Related]  

  • 19. Lowering Part D drug costs without direct CMS negotiations.
    Sipkoff M
    Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203
    [No Abstract]   [Full Text] [Related]  

  • 20. The cost of prescription drugs: rising concerns over equity, fairness and access to essential care.
    Work DR; Domino ME
    N C Med J; 2003; 64(6):270-4. PubMed ID: 14983614
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.